logo
Western New England University president Robert Johnson stepping down

Western New England University president Robert Johnson stepping down

Yahoo01-05-2025

SPRINGFIELD — Western New England University President Robert E. Johnson will step down from his role effective August 1.
Johnson shared the announcement with the university's board of trustees this week.
The trustees' goal is to name an interim president in time for there to be an overlap before Johnson departs. Details of the process will be shared in the coming weeks, the university said in a statement.
In a public statement, Western New England said Johnson began his five years of leadership just as COVID-19 hit. The university said it remained committed to in-person instruction, expanded mental health resources including mental health first aid training, and embraced a philosophy rooted in agility, adaptability and lifelong learning.
'It has been my honor to serve as president of Western New England University,' Johnson said in the statement. 'Together, we have navigated unprecedented challenges and embraced opportunities that have redefined what it means to prepare students for the future of work and society. I am deeply proud of what we have accomplished and confident that WNE's brightest days are still ahead.'
Johnson's accomplishments include the launch of a virtual reality lab, a financial technology center, the Center for Advanced Manufacturing, and a career center. Most recently, the university unveiled the Golden Bear Discovery Curriculum — the first major revision of the general education program in 25 years.
'WNE is an extraordinary place, and none of this would have been possible without the dedication of our exceptional faculty, staff and students,' Johnson said in an email to students and faculty. 'I have been proud to work alongside a leadership team and campus community defined by integrity, collaboration and resilience.'
Johnson earned $699,000 in compensation from Western New England University and related organizations, according to a 2022 tax document. That's the most recent tax form publicly available.
Springfield Partners for Community Action still serves as the connection place in city
Holyoke Landing, location of Popeyes and Starbucks, sold
Howdy Awards honor 10 for hospitality excellence in Springfield area
Read the original article on MassLive.
Read the original article on MassLive.
Read the original article on MassLive.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Yahoo

time36 minutes ago

  • Yahoo

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite's team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. A smiling baby with an array of baby care products in the foreground. The stock has gained over 9% in 2025 and currently offers a dividend yield of around 3.4%. Most analysts rate it as a hold, though LSEG data suggests there's still over 9% potential upside from current levels. Last month, Goldman Sachs raised its price target on Johnson & Johnson (NYSE:JNJ) from $172 to $176 and added the stock to its conviction list. The firm made the following statement in its May report: 'JNJ is a stable, defensive grower with the industry's strongest balance sheet allowing for continued high [return on invested capital] investments in the Innovative Medicines segment to augment revenue growth.' The firm highlighted that JNJ 'has a strong pipeline,' with 'meaningful revenue opportunities' in treatments for conditions such as multiple myeloma, lung cancer, and other serious illnesses. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Yahoo

timean hour ago

  • Yahoo

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite's team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. A smiling baby with an array of baby care products in the foreground. The stock has gained over 9% in 2025 and currently offers a dividend yield of around 3.4%. Most analysts rate it as a hold, though LSEG data suggests there's still over 9% potential upside from current levels. Last month, Goldman Sachs raised its price target on Johnson & Johnson (NYSE:JNJ) from $172 to $176 and added the stock to its conviction list. The firm made the following statement in its May report: 'JNJ is a stable, defensive grower with the industry's strongest balance sheet allowing for continued high [return on invested capital] investments in the Innovative Medicines segment to augment revenue growth.' The firm highlighted that JNJ 'has a strong pipeline,' with 'meaningful revenue opportunities' in treatments for conditions such as multiple myeloma, lung cancer, and other serious illnesses. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio

Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

Yahoo

time11 hours ago

  • Yahoo

Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedent, so they'll want to zero in on the Momentum Style Score. This Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries, which clearly means that the business is extremely well diversified. Its diversification helps it to withstand economic cycles more effectively. J&J has 26 platforms with more than $1 billion in annual sales. Meanwhile, J&J has one of the largest R&D budgets among pharma companies. JNJ boasts a Momentum Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Johnson & Johnson has seen some interesting price action recently; the stock is up 1.3% over the past one week and up 5.4% over the past four weeks. And in the last one-year period, JNJ has gained 6.6%. As for the stock's trading volume, 7,497,629 shares on average were traded over the last 20 days. Momentum investors also pay close attention to a company's earnings. For JNJ, eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.06 to $10.60 per share for 2025. JNJ boasts an average earnings surprise of 5.7%. With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding JNJ to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store